SAN DIEGO , Aug. 07, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Jeffrey Stein , Ph.D., president and chief executive officer of Cidara, is scheduled to present at the

Data from second part of successful Phase 2 STRIVE trial further substantiate the efficacy, safety and tolerability of once-weekly rezafungin for first-line treatment of invasive Candida infections Rezafungin met its objectives for efficacy, safety and tolerability Global Phase 3 ReSTORE trial

Company secures two oral and four poster presentations Presentations include new data highlighting the antiviral effect and immune system engagement of CB-012 for the prevention and treatment of flu SAN DIEGO --(BUSINESS WIRE)--Jun. 5, 2019-- Cidara Therapeutics, Inc.

SAN DIEGO , May 09, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended March 31, 2019 and provided an update on its corporate activities

Data featured in three oral and five poster presentations reinforce potential of novel antifungal for the treatment and prevention of serious invasive infections SAN DIEGO --(BUSINESS WIRE)--Apr. 16, 2019-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel

CB-012 demonstrates potent antiviral activity against influenza A and B viruses Cidara presenting preclinical results today at ECCMID 2019 SAN DIEGO --(BUSINESS WIRE)--Apr. 15, 2019-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including

SAN DIEGO , April 03, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Jeffrey Stein , Ph.D., president and chief executive officer of Cidara, is scheduled to present at the 18

Six poster presentations include new analyses from Phase 2 STRIVE clinical trial of rezafungin Four oral presentations include first scientific presentation of new data highlighting the potential of its Cloudbreak antiviral conjugates (AVCs) for influenza SAN DIEGO --(BUSINESS WIRE)--Mar.

SAN DIEGO --(BUSINESS WIRE)--Mar. 7, 2019-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that three rezafungin abstracts have been accepted for presentation at the 45 th Annual European Society for

SAN DIEGO , Feb. 28, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months and full year ended December 31, 2018 and provided an update on its